A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge

Katharine N. Bossart, Barry Rockx, Friederike Feldmann, Doug Brining, Dana Scott, Rachel LaCasse, Joan B. Geisbert, Yan Ru Feng, Yee Peng Chan, Andrew C. Hickey, Christopher C. Broder, Heinz Feldmann, Thomas W. Geisbert

Research output: Contribution to journalArticlepeer-review

104 Scopus citations


In the 1990s, Hendra virus and Nipah virus (NiV), two closely related and previously unrecognized paramyxoviruses that cause severe disease and death in humans and a variety of animals, were discovered in Australia and Malaysia, respectively. Outbreaks of disease have occurred nearly every year since NiV was first discovered, with case fatality ranging from 10 to 100%. In the African green monkey (AGM), NiV causes a severe lethal respiratory and/or neurological disease that essentially mirrors fatal human disease. Thus, the AGM represents a reliable disease model for vaccine and therapeutic efficacy testing. We show that vaccination of AGMs with a recombinant subunit vaccine based on the henipavirus attachment G glycoprotein affords complete protection against subsequent NiV infection with no evidence of clinical disease, virus replication, or pathology observed in any challenged subjects. Success of the recombinant subunit vaccine in nonhuman primates provides crucial data in supporting its further preclinical development for potential human use.

Original languageEnglish (US)
Article number146ra107
JournalScience Translational Medicine
Issue number146
StatePublished - Aug 8 2012

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge'. Together they form a unique fingerprint.

Cite this